GTC Expert Report Series · 2026

Cell & Gene Therapy Regulatory Guidance 2026

A 12-chapter mega-report built by leading CGT regulatory, CMC, and clinical experts — the definitive playbook for navigating FDA, EMA, and global CGT regulatory reality in 2026.

  12 Chapters   Built by GTC Expert Network   Target: Q3 2026   FDA · EMA · MHRA · PMDA

Sponsor a Chapter

Reach 2,000+ CGT drug developers, investors, and CDMOs exactly when they're reading about your area. Each chapter accepts a limited number of sponsors.

Logo Only — Free

  • Logo in the chapter's sponsor strip
  • No editorial content or commentary — logo placement only
Enquire about Logo Only

Vendor — €1,000

  • Logo in the chapter's sponsor strip
  • Company named inline, contextually, where your product/service is genuinely relevant
  • One factual, GTC-written line of description
Enquire about Vendor

General — €2,000

  • All Vendor benefits
  • Clearly labelled sponsor commentary section inside the chapter (your own words, fact-checked)
  • Named in GTC newsletter distribution
Enquire about General

Lead — €3,000

  • All General benefits
  • Primary logo placement on the chapter cover page
  • First right of refusal on the next report in the same topic area
  • Featured in the LinkedIn launch post distribution
Enquire about Lead

The 12 Chapters

Each chapter is built by GTC's expert network — regulatory leads, ex-FDA reviewers, CMC specialists, and clinical strategists. Vote counts reflect industry priority signals from the GTC TopicBoard.

Authored by 12 contributing experts from the GTC Network.